For suspected or existing coronary artery disease. ANDA 204465, held by Sofie. Ammonia N-13.
As of Nov 16, 2026, ANDA 204465 (Ammonia N 13), held by Sofie, was first approved by FDA on Oct 23, 2014, with 0 approved supplements and 0 published complete response letters.
Ammonia N 13 Injection, USP is indicated for diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. Ammonia N 13 Injection, USP is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 23, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ammonia N 1330mCi-300mCi/8ML (3.75-37.5mCi/ML) · injectable;intravenous | Ammonia N-13 | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters